Santhera Pharmaceuticals has formally withdrawn its marketing authorization application (MAA) for idebenone following its recent decision to end the global program under which it was developing the drug as a potential treatment for the rare disease of Duchenne muscular dystrophy (DMD).
The Swiss company made the decision to halt the program after an interim futility analysis indicated that idebenone would be...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?